268 related articles for article (PubMed ID: 32651157)
1. Frequency of Rhegmatogenous Retinal Detachment after Intravitreal Therapy in Neovascular Age-Related Macular Degeneration.
Mammo DA; Ringeisen AL; Parke DW
Ophthalmol Retina; 2020 Oct; 4(10):973-978. PubMed ID: 32651157
[TBL] [Abstract][Full Text] [Related]
2. Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor.
Storey PP; Pancholy M; Wibbelsman TD; Obeid A; Su D; Borkar D; Garg S; Gupta O
Ophthalmology; 2019 Oct; 126(10):1424-1431. PubMed ID: 31042567
[TBL] [Abstract][Full Text] [Related]
3. Rhegmatogenous Retinal Detachment after Intravitreal Injection.
Brown KR; Yannuzzi NA; Smiddy WE; Gregori NZ; Berrocal AM; Haddock LJ; Schwartz SG; Lee WH; Sridhar J; Wu DM; Flynn HW; Townsend JH
Ophthalmol Retina; 2021 Feb; 5(2):178-183. PubMed ID: 32673672
[TBL] [Abstract][Full Text] [Related]
4. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Arnould L; Viola F; Zarranz-Ventura J; Barthelmes D; Creuzot-Garcher C; Gillies M;
Ophthalmol Retina; 2022 Nov; 6(11):1044-1053. PubMed ID: 35589075
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and surgical outcomes of rhegmatogenous retinal detachments that develop after intravitreal injections.
Baba T; Miura G; Tatsumi T; Sakurai M; Yamamoto S
Jpn J Ophthalmol; 2021 Jul; 65(4):492-496. PubMed ID: 33745092
[TBL] [Abstract][Full Text] [Related]
6. CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITIS.
Koulisis N; Moysidis SN; Govindaraju VK; Dersch AM; Capone A; Covert DJ; Dadgostar H; Dass AB; Drenser KA; Engstrom RE; Faia LJ; Garretson BR; Guerami AH; Hanscom TA; Mahmoud TH; Margherio AR; Oh KT; Randhawa S; Raphaelian PV; Rhoades WR; Ruby AJ; Sanfilippo CJ; Sneed SR; Trese MT; Wolfe JD; Williams GA; Yedavally S; Hassan TS
Retina; 2021 Jun; 41(6):1242-1250. PubMed ID: 33079789
[TBL] [Abstract][Full Text] [Related]
7. Erosive Retinopathy and Retinal Detachment From Depot Intravitreal Triamcinolone Acetonide Injection at the End of Pars Plana Vitrectomy.
Sisk RA; Patel YP; Foster RE; Petersen MR
Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):613-619. PubMed ID: 31671193
[TBL] [Abstract][Full Text] [Related]
8. Primary Retinal Detachment Outcomes Study: Pseudophakic Retinal Detachment Outcomes: Primary Retinal Detachment Outcomes Study Report Number 3.
Joseph DP; Ryan EH; Ryan CM; Forbes NJK; Wagley S; Yonekawa Y; Mittra RA; Parke DW; Emerson GG; Shah GK; Blinder KJ; Capone A; Williams GA; Eliott D; Gupta OP; Hsu J; Regillo CD
Ophthalmology; 2020 Nov; 127(11):1507-1514. PubMed ID: 32437865
[TBL] [Abstract][Full Text] [Related]
9. Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease.
Kumar A; Sehra SV; Thirumalesh MB; Gogia V
Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):685-90. PubMed ID: 22169980
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
11. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
[TBL] [Abstract][Full Text] [Related]
12. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
13. Macular Edema after Successful Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment: Factors Affecting Edema Development and Considerations for Treatment.
Chatziralli I; Theodossiadis G; Dimitriou E; Kazantzis D; Theodossiadis P
Ocul Immunol Inflamm; 2021 Jan; 29(1):187-192. PubMed ID: 31577459
[No Abstract] [Full Text] [Related]
14. Intravitreal injection associated rhegmatogenous retinal detachment: outcomes of a European analysis.
Vounotrypidis E; Freissinger S; Cereda M; Monteduro D; Kortuem K; Priglinger S; Mayer B; Wolf A
Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3655-3664. PubMed ID: 34216254
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
[TBL] [Abstract][Full Text] [Related]
16. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
[TBL] [Abstract][Full Text] [Related]
17. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.
Ozturk M; Harris ML; Nguyen V; Barthelmes D; Gillies MC; Mehta H
Clin Exp Ophthalmol; 2018 May; 46(4):407-411. PubMed ID: 29044979
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration.
Essex RW; Nguyen V; Walton R; Arnold JJ; McAllister IL; Guymer RH; Morlet N; Young S; Barthelmes D; Gillies MC;
Ophthalmology; 2016 Nov; 123(11):2393-2400. PubMed ID: 27554034
[TBL] [Abstract][Full Text] [Related]
19. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
